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Genetic factors associated with Body Mass Index (BMI) have been widely studied over 
the last decade. We examined whether genetic variants previously associated with BMI 
in the general population are associated with cardiometabolic parameter worsening in 
the psychiatric population receiving psychotropic drugs, a high-risk group for metabolic 
disturbances. Classification And Regression Trees (CARTs) were used as a tool 
capable of describing hierarchical associations, to pinpoint genetic variants best 
predicting worsening of cardiometabolic parameters (i.e total, HDL and LDL-cholesterol, 
triglycerides, body mass index, waist circumference, fasting glucose, and blood 
pressure) following prescription of psychotropic drugs inducing weight gain in a 
discovery sample of 357 Caucasian patients. Significant findings were tested for 
replication in a second Caucasian psychiatric sample (n=140).  
SH2B1 rs3888190C>A was significantly associated with LDL levels in the discovery and 
in the replication sample, with A-allele carriers having 0.2 mmol/l (p=0.005) and 0.36 
mmol/l (p=0.007) higher LDL levels compared to others, respectively. G-allele carriers of 
RABEP1 rs1000940A>G had lower fasting glucose levels compared to others in both 
samples (-0.16 mmol/l; p<0.001 and -0.77 mmol/l; p=0.03 respectively). The present 
study is the first to observe such associations in human subjects, which may in part be 
explained by a high risk towards dyslipidemia and diabetes in psychiatric patients 
receiving psychotropic treatments compared to population-based individuals. These 
results may therefore give new insight into the etiology of LDL-cholesterol and glucose 





Cardiovascular diseases constitute a major health concern associated with high 
morbidity and mortality. Comorbidities such as obesity, dyslipidemia, diabetes and 
hypertension are complex clinical conditions and major contributing risk factors for the 
development of cardiovascular diseases. Such medical conditions result from the 
interaction between numerous genetic and environmental factors (e.g. sedentary 
lifestyle with excessive dietary intake) (1, 2). Genetic risk factors were actually reported 
to account for up to 40 to 70% of inter-individual variability for the most extensively 
studied obesity-related phenotype, namely the BMI (3, 4). The largest meta-analysis of 
Genome-Wide Association Studies (GWAS) to date has reported 97 different loci 
associated with BMI in 339,224 individuals (5). 
In psychiatry, patients suffering from severe mental illness have a reduced life 
expectancy of 10 to 25 years compared to the general population due mainly to 
cardiovascular diseases resulting from the psychiatric disorder and/or comorbidities, but 
also from the prescription of psychotropic treatments (6). Thus, many antipsychotics, in 
particular atypical antipsychotics, some mood stabilizers and antidepressants induce 
metabolic dysfunctions by inducing weight gain (7), dyslipidemia (8), type 2 diabetes (9-
11), and/or hypertension (12) to varying degrees. For instance, clozapine and 
olanzapine are associated with the greatest risk for developing weight gain and other 
metabolic effects (7). All of these factors result in serious morbidity such as 
cardiovascular diseases (13) and a decreased medication adherence. Dyslipidemia, 
type 2 diabetes and hypertension can develop either as a direct or collateral 
consequence of the use of psychotropic drugs. Although precise mechanisms underlying 
metabolic side effects induced by psychotropic drugs are only partially elucidated to 
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date, the dual antagonism on serotonin and dopamine receptors was shown to stimulate 
appetite leading to weight gain and other long-term comorbidities (14). Furthermore, 
independent antagonism actions on adrenergic and muscarinic receptors were directly 
related with decreasing insulin secretion and pancreatic β-cell response (15). Over the 
last decade, pharmacogenetics of psychotropic-induced weight gain has been 
extensively studied using candidate gene approaches, in particular within dopamine and 
serotonin receptors (16, 17). In addition, numerous single nucleotide polymorphisms 
(SNPs) within genes involved in other pathways of metabolism regulation (e.g. enzymes, 
receptors or transcriptional coactivators involved in leptin-melanocortin pathways, genes 
involved in cholesterol and/or in glucose homeostasis) were also associated with weight 
gain in psychiatric patients taking psychotropic drugs (18-22).  
A growing body of evidence suggests that obesity and psychiatric diseases share 
common etiological pathways, which may be illustrated by the observed synergistic 
influence of genes associated with obesity and with psychiatric illness on 
cardiometabolic parameters (23). In addition, recent pharmacogenetic studies have 
shown stronger influence on obesity phenotypes of some BMI-associated genes in the 
psychiatric population treated with weight gain inducing psychotropic drugs compared to 
the general population (19-21). Unfortunately, it is unknown to which extent the 97 
variants associated with BMI in the general population are associated with other 
cardiometabolic phenotypes in the psychiatric population, despite that such populations 
are at very high risk for cardiometabolic disorders. Because cardiometabolic traits have 
a complex etiology, with an important variability, the aim of the present study was to 
determine whether population-based genetic variants related to BMI are associated with 
cardiometabolic phenotypes in patients from two psychiatric samples who were 
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prescribed known weight gain inducing psychotropic drugs. The analyses were 
performed using methods capable of detecting hierarchical associations, in order to 
further refine the underlying biological mechanisms of cardiometabolic phenotypes in 
psychiatry. 
 
MATERIALS AND METHODS 
Psychiatric samples 
A prospective cohort study is ongoing in the Lausanne Psychiatric University Hospital 
since 2007. Patients treated with atypical antipsychotics (amisulpride, aripiprazole, 
clozapine, olanzapine, quetiapine, paliperidone, risperidone), mood stabilizers (lithium, 
valproate) or/and mirtazapine were included. Baseline and follow-up clinical 
observations (1, 3, 6 and/or 12 months) were obtained during a medical examination 
based on the department guideline for metabolic follow-up performed on a routine basis 
(24). Blood samples were collected at 1st, 3rd and 12th months. Most patients had already 
received other psychotropic treatments before the current treatment. Ethnicity data were 
obtained from medical files. Diagnoses were based on the ICD-10 classification (F00-
F09 organic disorder; F20.0-F24.9 and F28-F29 psychotic disorders; F25.0-F25.9 
schizoaffective disorder; F30.0-F31.9 bipolar disorder; F32.0-F33.9 depressive 
disorder). Written informed consents for inclusion in the study and also for the genetic 
analyses were obtained from patients or their legal representatives. The study was 
approved by the Ethics Committee of Lausanne University Hospital. Further description 
of the cohort study was published elsewhere (22, 25). 
 
Discovery and replication samples 
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97 SNPs associated with BMI in a recent population-based meta-analysis (5) were 
tested for association with worsening of cardiometabolic variables in the discovery 
sample. The discovery sample consisted of 357 Caucasian patients from the above-
described prospective cohort study, with available clinical data for at least two periods 
including baseline data.  Positive results (i.e. for a smaller subset of SNPs) were tested 
for replication in the replication sample, composed of 140 Caucasian patients from the 
same cohort study, with available clinical data for at least two periods of treatment but 
without baseline data (all patients with baseline data were already included in the 
discovery sample). Changes of metabolic parameters are more important at the 
beginning of treatment and including patients with baseline data in the discovery cohort 
increases the power to detect significant associations between SNPs  and 
cardiometabolic parameters. Thereafter, only the strongest signals were confirmed using 
the replication sample.  
 
SNP selection and genotyping 
97 SNPs were selected according to the previously mentioned population-based meta-
analysis (5). DNA from blood samples of psychiatric patients was extracted using the 
Flexigene DNA Kit or QIAamp DNA Blood Mini QIAcube Kit (Qiagen AG, Switzerland) as 
described by the manufacturers’s instructions. Genotypes of 96 SNPs were available in 
the Illumina 200K CardioMetaboChip (26). The CardioMetabochip is a custom 
Illumina iSelect genotyping array designed to test DNA variation of 200’000 SNPs from 
regions identified by large scale meta-analyses of genome wide association studies 
(GWAS) for metabolic and cardiovascular traits. CardioMetabochip genotyping was 
performed at the iGE3 genomics platform of the University of Geneva 
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(http://www.ige3.unige.ch/genomics-platform.php). Quality control excluded samples 
from the analysis if gender was inconsistent with genetic data from X-linked markers, if 
autosomal heterozygosity was extreme, genotype call rate <0.96, Gene Call (GC) score 
<0.15 and/or minor allele frequency (MAF) <0.10. The one remaining SNP not available 
in the CardioMetaboChip, namely rs11847697, was analysed using a TaqMan SNP 
Genotyping Assay (C_1293175_10) on ViiA™ 7 Real-Time PCR System, as described 
by the manufacturer instructions.  
 
Functional assessment of significant SNPs 
eQTL analysis 
Cis-association data of the influence of significant SNPs on the expression of nearby 
genes were extracted from the Genotype-Tissue Expression (GTEx) project, a public 
source (http://www.gtexportal.org/home/) with available expression Quantative Trait Loci 
(eQTL) data of 7051 samples from 44 different tissues and for genome-wide genetic 
variations in the general population (Illumina OMNI 5M SNP Array)(27). 
 
RegulomeDB annotation 
The Regulome database (http://www.regulomedb.org/) was used to assess the 
functional activity of significant SNPs (28). This database defines SNPs with known 
and/or predicted regulatory elements located in intergenic regions of the human 
genome. Known and predicted regulatory elements include regions of DNAase 
hypersensitivity, binding sites of transcription factors and promoter regions biochemically 
characterized to the regulation of transcription. Sources for these data include public 





Statistical analyses were performed using Stata 12 (StataCorp, College Station TX, 
USA) and R version 3.1.1. Hardy-Weinberg equilibrium (HWE) testing was performed for 
the 97 SNPs using Pearson’s chi-squared test. SNPs for which p-value was higher than 
0.05 were considered in HWE. 
Classification And Regression Trees (CARTs) are used to segregate SNPs that best 
predict the worsening of cardiometabolic variables during different periods of the 
psychotropic treatment. CARTs can be grown using the so called Recursive Partitioning 
and Regression Trees algorithms (29). These algorithms are implemented in a few 
softwares including R environment for statistical programming and data analysis (rpart 
library). At each node, the split rule is applied which is based on the Generalized Gini 
index, the split can be performed if number of observations exceeds a certain threshold 
(the threshold in this study was 20). Pruning can be used in function of the desired 
complexity of the tree. Complexity of the constructed tree at each node is represented 
by the so called Complexity Parameter which is equivalent to the decrease in relative 
error rate of the tree if the split at each that node survives after the tree is pruned.  
CARTs were first performed on the discovery sample to identify clinical (age, sex, 
smoking status) and genetic (97 SNPs) variables best predicting worsening of 
cardiometabolic features during the psychotropic treatment (i.e. increase of BMI, waist 
circumference (WC), total cholesterol (TC), fasting triglycerides (TG), low-density 
lipoprotein (LDL), fasting glucose (GLC), systolic blood pressure (SBP) and/or of 
diastolic blood pressure (DBP), and/or decrease of high-density lipoprotein (HDL)). Of 
note, patients receiving lipid-lowering, antidiabetic and/or antihypertensive drugs were 
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excluded from TC, TG, LDL, HDL analyses, GLC analyses and SBP and DBP analyses, 
respectively (S1 Table). In order to determine short- and long-term risk factors 
associated with metabolic disturbances, CARTs were performed at several periods of 
treatment (i.e. from ≥10 to <45 days; from ≥45 to <135 days and from ≥135 to <535 days 
of psychotropic treatment). Variables in the first three layers of the CART tree structure 
for each cardiometabolic phenotype and each period of psychotropic treatment were 
considered in further covariate-adjusted statistical analyses. Associations between the 
most important SNPs (in the first three layers) and cardiometabolic variables were 
assessed in the discovery sample (using a dominant or recessive model according to 
CART results) by fitting a generalized additive mixed model (GAMM) adjusting for 
possible confounders such as age, sex and smoking status (30), allowing a smooth 
trend for the response in time based on multiple observations for each patient. 
Significant associations were then tested in the replication sample using the same 
model. GAMMs were fitted using the mgcv package of R, in which parameter 
uncertainties (confidence intervals and p-values) were computed using bootstrap (1000 
replicates or 10000 replicates whenever possible with replacement, performed on 




Characteristics of psychiatric samples 
S2 Table displays demographic and clinical characteristics of the two psychiatric 
Caucasian samples. As published elsewhere (25), values of cardiometabolic parameters 
in both psychiatric samples generally increased during the psychotropic treatment. 
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Patients were slightly older in the replication sample (median of 52 years) compared to 
the discovery sample (median of 47 years; p=0.04). Psychotic (F20.0-F24.9 and F28-
F29) was the most frequent diagnosis (37% in the combined sample), and quetiapine 
was the most frequently prescribed psychotropic drug (33% in the combined sample). 
No difference of clinical or of demographical variables was observed between the 
discovery and replication samples (p>0.05), except in the second psychotropic treatment 
period, namely between 45 and 135 days of treatment, in which BMI and waist 
circumference were higher in the replication sample (25.5 kg/m2; 95 cm) compared to 
the discovery sample (23.7 kg/m2; 91 cm; p-values=0.04 and 0.03, respectively).  
 
Variables predicting cardiometabolic phenotype worsening in the discovery 
sample 
Three out of the 97 SNPs were not in Hardy Weinberg equilibrium and were therefore 
not used in analyses (i.e rs1075847, rs13201877 and rs657452). CARTs fitted on the 
different cardiometabolic phenotypes (i.e. BMI, WC, HDL, TC, TG, LDL, GLC, SBP and 
DBP) highlighted 57 different SNPs that best predicted worsening of at least one of the 
latter-mentioned cardiometabolic variable in the discovery sample during three distinct 
consecutive periods of psychotropic treatment. An example of a CART is presented in 
S1 Fig, showing, for instance, that patients carrying the variant allele of ADCY3 
rs10182181A>G (i.e. G) have a mean TC increase of 3.9%, whereas those who carry 
the AA genotype have a mean TC increase of 13.7% during the first period of 
psychotropic treatment. A summary of CART results is displayed in Table 1. 
 
Association of SNPs with cardiometabolic phenotypes in psychiatric samples 
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In the discovery sample, 18 out of the 57 different SNPs were significantly associated 
with at least one cardiometabolic phenotype using multiple linear models adjusted for 
age, sex, BMI and smoking status (p<0.05) (Table 2). Two out of the 18 SNPs were 
significantly replicated in the replication sample, with SH2B1 rs3888190C>A and 
RABEP1 rs1000940A>G being significantly associated with LDL levels (p=0.007) and 
FG levels (p=0.03), respectively (Table 3). The 16 remaining SNPs were not replicated 
(data not shown) and were therefore not considered in further analyses. Genotype 
frequencies of SH2B1 rs3888190C>A (GRCh38.p7 16:28878165) and RABEP1 
rs1000940A>G (GRCh38.p7 17:5379957) in the discovery and replication samples are 
presented in the S3 Table. Both SNPs were in HWE in the two psychiatric samples, and 
their MAF were in accordance with those reported in HapMap for Caucasians. 
 
Association of SH2B1 rs3888190C>A with LDL levels in psychiatric samples 
In the discovery sample, rs3888190C>A was significantly associated with LDL levels, 
with A-allele carriers having 0.20 [0.07; 0.36] mmol/l higher LDL levels compared to 
patients carrying the CC genotype (p=0.005) (Table 3). This observation was replicated 
in the second psychiatric sample (0.36 [0.08; 0.66] mmol/l; p=0.007) (Table 3). S2 Fig.a 
illustrates the evolution of abnormal LDL level (i.e. LDL levels ≥ 3 mmol/l and/or with any 
prescribed lipid-lowering drug) prevalence according to rs3888190C>A genotypes 
during psychotropic treatment in the combined sample. During psychotropic treatment, 
the proportion of patients with abnormal LDL values significantly increased for both 
rs3888190-CC (from 40% at baseline to 54% in the last treatment period; p=0.04) and 
rs3888190-A allele carriers (from 46% to 60%, respectively; p=0.02), reflecting the 
development of dyslipidemia-induced psychotropic drug. Within subperiods of treatment, 
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no difference of abnormal LDL proportion was detected across rs3888190C>A 
genotypes, possibly due to insufficient power. In contrast, when considering all 
observations from multiple treatment periods together (S2 Fig.b), the overall proportion 
of patients with abnormal LDL levels was lower for rs3888190-CC carriers (47%) 
compared to rs3888190-A allele carriers (53%; p=0.03). 
 
Association of RABEP1 rs1000940A>G with fasting glucose levels in psychiatric 
samples 
In the discovery sample, rs1000940A>G was significantly associated with fasting 
glucose. G-allele carriers had 0.16 [0.06; 0.28] mmol/l lower fasting glucose levels 
compared to patients carrying the AA genotype (p<0.001) and this association was 
replicated in the second psychiatric sample (0.77 [0.03; 1.39] mmol/l; p=0.03) (Table 3). 
S3 Fig.a displays the prevalence of abnormal fasting glucose levels (i.e. fasting GLC 
levels ≥ 5.6 mmol/l and/or with any prescribed antidiabetic drug) according to 
rs1000940A>G during the psychotropic treatment. As for SH2B1 rs3888190C>A and 
LDL, no significant difference of abnormal glucose level prevalence across 
rs1000940A>G genotypes was observed in subperiods of psychotropic treatment. 
However, the overall proportion of patients with abnormal glucose levels was 
significantly lower for patients carrying rs1000940-G allele (20%) compared to those 
carrying the AA genotype (27%; p=0.03) when considering all periods of treatment 
together (S3 Fig.b). Moreover, when considering each genotype separately (i.e. in 
carriers of rs1000940 AA genotype and in carriers of rs1000940 G allele), there was no 
significant difference of the prevalence of hyperglycemia after a short or after a longer 
period of treatment (p=0.77 and 0.96 for AA and G allele carriers, respectively), possibly 
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explained by a worsening of glycemia profile occurring during a longer period of 
treatment than the one taken into account during the present study. 
Even though being non significant due to non-adjusted analyses as well as an 
insufficient number of observation, S2 and S3 Fig suggest that both SH2B1 
rs3888190C>A and RABEP1 rs1000940A>G could exert an influence on LDL and on 
glucose, respectively, already before the current psychotropic treatment initiation. These 
baseline differences may possibly be explained, at least in part, by the fact that most 
patients were not drug naïve when starting the current psychotropic treatment. Of note, 
no difference of LDL nor of glucose levels were observed between psychotropic 
medication groups (constructed according to their propensity to induce metabolic 
alterations, i.e. high-risk group (olanzapine, clozapine and valproate) versus medium-
risk group (quetiapine, risperidone, mirtazapine, lithium) versus low-risk group 
(amisulpride, aripiprazole)), data not shown.  
Although neither SH2B1 rs3888190C>A nor RABEP1 rs1000940A>G were detected as 
having a possible influence on BMI in CART analyses, both SNPs were tested for 
association with BMI in the discovery psychiatric sample. No significant association was 




The present study aimed to explore whether SNPs previously associated with BMI and 
other cardiometabolic variables in the general population (5) are associated with the 
worsening of cardiometabolic phenotypes in a psychiatric population receiving weight 
gain inducing psychotropic treatments. In particular, we aimed to better refine underlying 
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mechanisms linking and/or discerning genetics of BMI with regard to other 
cardiometabolic comorbidities in the psychiatric population, considering that the 
prevalence of metabolic syndrome has been reported twice as high in this population 
compared to the general population (31).  
Our preliminary exploration using CART analyses highlighted and ranked 57 different 
SNPs that predicted the best metabolic parameter worsening during psychotropic 
treatment in the discovery sample. In the latter sample, 18 SNPs were significantly 
associated with cardiometabolic phenotypes but the remaining 39 SNPs were not, 
probably due to adjustment for covariates (i.e. age, sex, BMI and/or smoking status) in 
GAMM analyses, which was not performed in exploratory CART analyses. Out of the 18 
SNPs, SH2B1 rs3888190C>A and RABEP1 rs1000940A>G were replicated in the 
second psychiatric replication sample. The 16 remaining SNPs were not replicated, 
possibly due to the lower sample size of the latter sample compared to the discovery 
sample and the probable minor influence of these SNPs on cardiometabolic variables.  
Thus, SH2B1 rs3888190C>A and RABEP1 rs1000940A>G were significantly associated 
with low-density lipoprotein levels and fasting glucose levels, respectively, in two 
separate psychiatric samples. As recent population-based studies did not observe such 
associations (5, 32) this is, to our knowledge, the first genetic study that suggested an 
influence of SH2B1 rs3888190C>A on LDL as well as of RABEP1 rs1000940A>G on 
fasting glucose levels. These different results between general and psychiatric 
populations may in part be explained by a lower risk towards dyslipidemia and diabetes 
in population-based individuals compared to psychiatric patients receiving psychotropic 
treatments(33). Of note, since a 1% reduction in LDL-cholesterol on average was shown 
to reduce risks for hard coronary heart disease events by approximately 1% in short-
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term controlled trials (34), the observed difference of LDL levels between SH2B1 
rs3888190C>A genotypes  appears clinically relevant. 
In order to differentiate SNPs according to their short- and/or long-term influence on 
metabolic features, CART analyses were conducted after several distinct periods of 
psychotropic treatment. Both SH2B1 rs3888190C>A and RABEP1 rs1000940A>G 
appeared to exert an influence already before the current psychotropic treatment 
initiation, which may be explained by the fact that most patients were not drug naïve 
when starting the current psychotropic treatment. Further studies are required to 
characterize how these genetic variants influence these two metabolic parameters in 
drug naïve patients. It is of particular interest to note that our results within this 
observational psychiatric sample reflect real clinical conditions. 
The LDL-increasing allele of SH2B1 rs3888190C>A in the psychiatric population, 
namely the A allele was associated with higher BMI values (0.03 kg/m2; p=3.14*10-23) in 
population-based samples (5), which is in accordance with epidemiological expectations. 
On the other hand, the glucose-increasing genotype of RABEP1 rs1000940A>G in the 
psychiatric population, namely AA was associated with lower BMI values in the general 
population (-0.019 kg/m2; p=1.3*10-8) (5). This unexpected result may be explained by a 
differential influence of RABEP1 rs1000940A>G on these two cardiometabolic 
parameters between population-based and psychiatric samples. Despite BMI being a 
well-described parameter associated with metabolic comorbidities including fasting 
glycemia in large prospective population studies (35), some recent conflicting genetic 
association results have been described in population-based samples (32). Thus, 
several loci have a more pronounced effect on body fat percentage than on BMI, 
suggesting a specific effect on adiposity rather than on overall body mass (32). For 
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instance, a genetic polymorphism 500kb upstream of IRS1 and influencing its 
expression was on one hand significantly associated with an increased overall adiposity 
(body fat percentage) and, on the other hand, associated with a protective effect on 
cardiometabolic health, including a reduced risk of type 2 diabetes and cardiovascular 
diseases (32). These unexpected results were explained by an effect on fat distribution, 
as the body fat percentage increasing allele was associated with increased 
subcutaneous but not with metabolically more harmful visceral fat (36). Many other 
similar inconsistent cross-phenotypic genetic associations were described in population-
based GWAS meta-analyses (5, 32) and strikingly, most of inconsistent cross-
phenotypic genetic associations encompass genes that influence insulin receptor 
signaling (32). Further studies are therefore needed to elucidate underlying biological 
mechanisms of such unexpected cross-phenotypic associations, in particular between 
adiposity and insulin resistance disorders. 
An increasing number of studies indicate that metabolic and psychiatric diseases share 
common etiological pathways and have related neurobiological bases (23). SH2B1 
rs3888190C>A as well as its 77 proxies lie in a highly conserved genetic region 
displaying a considerable regulatory function. SH2B1 rs3888190C>A may alter the 
expression of many genes involved in cholesterol homeostasis, including Interleukin 27 
(IL27), SH2B1 and Apolipoprotein B receptor (APOBR) (S4 Fig) (37-43), either through a 
cis-effect in the liver and/or through methylation-mediated long-range interaction with its 
promoter (44). Apart from being involved in the regulation of atherosclerosis, this 
cytokine was associated with LDL levels in mice and humans (40-42). Besides, some 
genes involved in the immune system have been associated with schizophrenia, bipolar 
disorder and major depressive disorder (MDD) in two recent genome-wide association 
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studies (45, 46), suggesting that cytokines may play a role in psychiatric disorders. 
Similarly, a recent meta-analysis reported analogies in the pattern of cytokine alterations 
in the above mentioned  psychiatric disorders (47). Taken together, published results 
suggest that LDL regulation and psychiatric illnesses may share common regulatory 
genes including IL27, which constitutes a possible candidate to explain the specific 
influence of SH2B1 rs3888190C>A on LDL in patients with psychiatric disorders but not 
in individuals from the general population. A growing body of evidence suggest that 
RABEP1 rs1000940A>G and its 7 proxies (r2>0.95) may be involved in the regulation of 
glucose. RABEP1 was shown to interact with RAB5a, a protein required for the 
regulation of gluconeogenic gene (48) and for insulin sensitivity (49, 50). Additionally, 
NUP88 was shown to interact with several proteins including the CREB binding protein 
(CREBBP) involved in insulin sensitivity (51). In addition, eQTL data of these SNPs 
showed higher expression of NUP88 in the brain (cerebellar hemisphere) and a lower 
expression of RABEP1 in the thyroid and the pituitary, two genes (tagged in part by 
rs1000940A>G) interacting with different proteins involved in insulin sensitivity (S5 Fig) 
(48-51). Within the large genetic region of RABEP1 rs1000940A>G, three proxies may 
influence expression levels of ATF2, a transcription factor involved in part in the 
regulation of insulin resistance (51-55). Interestingly, an overexpression of the latter 
transcription factor in nucleus accumbens of rats enhanced antidepressant-like 
responses, suggesting that this transcription factor plays a role in the regulation of 
emotional behavior as well (56). Likewise, chronic administration of antidepressants 
impaired levels of ATF2 in the prefrontal cortex in rats, and similarly, levels of 
phosphorylated ATF2 were decreased in patients medicated with antidepressants 
compared to non-medicated patients in post-mortem human brains (57). The latter 
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studies illustrate the possible role of ATF2 in the complex interminglement between 
glucose homeostasis and psychiatric illnesses and may therefore explain the specific 
influence of RABEP1 rs1000940A>G on glucose levels in particular in patients with 
psychiatric disorders but not in individuals from the general population. More studies 
with larger psychiatric samples are needed to confirm our findings and to identify true 
causal variants, which will help to better understand mechanisms underlying the 
metabolic regulation of cholesterol and glucose, in particular in the psychiatric 
population. 
Several limitations of the present study should be considered. Firstly, this study was 
limited to Caucasian patients and results cannot be generalized to other ethnicities. 
Secondly, the functional activity of SH2B1 rs3888190C>A and of RABEP1 
rs1000940A>G could not be assessed in the psychiatric population. Third, association 
with SH2B1 rs3888190C>A did not survive to multiple testing correction. However, the 
present results were replicated in a second psychiatric sample and functional analyses 
strengthen the validity of our data. Moreover, our results within this observational 
psychiatric sample reflect real clinical conditions. 
In conclusion, this is the first genetic study to identify an association between SH2B1 
rs3888190C>A and LDL levels as well as between RABEP1 rs1000940A>G and 
glucose levels. Our results are in agreement with the previously reported roles of the 
many probable affected genes in metabolism and provide new insight into the 
implication of these genes in the human regulation of cholesterol and glucose, in 
particular in the psychiatric population receiving psychotropic drugs. Finally, the 
considerable regulatory function of these genetic regions emphasizes the probable 
involvement of many regulatory genes and supports further studies to better understand 
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mechanisms underlying the metabolic regulation of cholesterol and glucose, in particular 
in the psychiatric population. 
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            Table 1. SNPs and cardiometabolic variables: CART analyses. 
 
 
TC: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triglycerides;  BMI: body mass index; WC: waist circumference; FG: 
fasting glucose; SBP: systolic blood pressure; DBP: diastolic blood pressure. 
This table displays the 57 SNPs predicting the best worsening of cardiometabolic parameters (within the first three layers) according to CART analyses in the discovery sample.  























SNP gene1 SNP gene1 SNP gene1 SNP gene1 SNP gene1 SNP gene1 SNP gene1 SNP gene1 SNP gene1
rs10182181 ADCY3 rs10132280 STXBP6 rs1000940 RABEP1 rs1000940 RABEP1 rs1016287 LINC01122 rs11583200 ELAVL4 rs1000940 RABEP1 rs10132280 STXBP6 rs1000940 RABEP1
rs10968576 LINGO2 rs10968576 LINGO2 rs10182181 ADCY3 rs11688816 EHBP1 rs10182181 ADCY3 rs12429545 OLFM4 rs11688816 EHBP1 rs10182181 ADCY3 rs10938397 GNPDA2
rs11688816 EHBP1 rs11165643 PTBP2 rs10968576 LINGO2 rs12429545 OLFM4 rs11688816 EHBP1 rs1808579 C18orf8 rs17203016 CREB1 rs1441264 MIR548A2 rs10968576 LINGO2
rs12401738 FUBP1 rs11688816 EHBP1 rs1441264 MIR548A2 rs1528435 UBE2E3 rs12885454 PRKD1 rs2033529 TDRG1 rs17405819 HNF4G rs17203016 CREB1 rs10968576 LINGO2
rs17024393 GNAT2 rs1441264 MIR548A2 rs2176598 HSD17B12 rs29941 KCTD15 rs12940622 RPTOR rs2033732 RALYL rs2820292 NAV1 rs29941 KCTD15 rs1167827 HIP1
rs17094222 HIF1AN rs1460676 FIGN rs2287019 QPCTL rs3101336 NEGR1 rs1441264 MIR548A2 rs205262 C6orf106 rs3101336 NEGR1 rs3810291 ZC3H4 rs17405819 HNF4G
rs1808579 C18orf8 rs1514175 TNNI3K rs3736485 DMXL2 rs3888190 SH2B1 rs1808579 C18orf8 rs2241420 MAP2K5 rs543874 SEC16B rs7164727 LOC100287559 rs17724992 PGPEP1
rs1928295 TLR4 rs16907751 ZBTB10 rs3888190 SH2B1 rs5014937 CALCR rs2033732 RALYL rs29941 KCTD15 rs6567160 MC4R rs3810291 ZC3H4
rs205262 C6orf106 rs2112347 POC5 rs492400 USP37 rs7103411 BDNF rs4740619 C9orf93 rs492400 USP37 rs7164727 LOC100287559 rs3849570 GBE1
rs492400 USP37 rs29941 KCTD15 rs7164727 LOC100287559 rs7903146 TCF7L2 rs7239883 LOC284260 rs4787491 INO80E
rs7164727 LOC100287559 rs4787491 INO80E rs7243357 GRP rs9400239 FOXO3 rs7903146 TCF7L2 rs7113874 TRIM66
rs7903146 TCF7L2 rs6804842 RARB rs7715256 GALNT10
rs9914578 SMG6 rs7103411 BDNF rs9374842 LOC285762
rs7715256 GALNT10
rs7903146 TCF7L2
FG SBP DBPTC HDL LDL TG BMI WC
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Among SNPs from CART analyses (in Table 1), 18 SNPs were significantly associated with cardiometabolic variables in the discovery sample using GAMM models, with SNPs 
considered as dominant or recessive according to CART results. 












SNP gene(s)1 SNP gene(s)1 SNP gene(s)1 SNP gene(s)1 SNP gene(s)1 SNP gene(s)1 SNP gene(s)1 SNP gene(s)1 SNP gene(s)1
β p-value β p-value β p-value β p-value β p-value β p-value β p-value β p-value β p-value





rs7103411 C>T BDNF rs1016287 T>C LINC01122 rs2241420 G>A
MAP2K5; 
LBXCOR1 rs1000940 A>G RABEP1 rs29941 A>G KCTD15 rs1000940 A>G RABEP1
ref :TT ref :GG ref :CC ref :CC ref :TT/TC ref :GG/GA ref :AA ref :AA/AG ref :AA













rs12429545 G>A OLFM4 rs7903146 C>T TCF7L2 rs3810291 G>A ZC3H4
ref :AA ref :CC/CT ref :CC ref :CC/CA ref :TT ref :GG ref :CC/CT ref :GG
-0.22 (-0.37 - (-)0.05) -0.23 (-0.31 - (-)0.14) <0.001 -0.11 (-0.24 - 0.02) 0.13 (-0.04-0.29) 0.05 0.99 (0.22-1.88) -2.18 (-4.05 - (-)0.17) 0.15 (-0.01-0.31) -1.63 (-4.07 - 0.32)





ref:GG/GA ref :GG/GA ref :GG















n=309 n=306 n=301 n=290 n=330 n=325 n=287
TC HDL LDL TG BMI WC
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Table 3. Association of SNPs with metabolic phenotypes in two independent Caucasian psychiatric samples 
SNP Phenotype n Discovery sample p-value n Replication sample p-value 
β (95% CI) (mmol/l) β (95% CI) (mmol/l) 
SH2B1 rs3888190C>A 
LDL 301
    
105
    
CC ref 0.005 ref 0.007 CA/AA 0.20 (0.07 - 0.36) 0.36 (0.08 - 0.66) 
RABEP1 rs1000940A>G 
FG 287
    
82 
    
AA ref <0.001 ref 0.03 AG/GG -0.16 (-0.28 - -0.06) -0.77 (-1.39 - 0.03) 
 
In this Table, 2 SNPs significantly associated with cardiometabolic variables in the replication sample using GAMM models are displayed. For clarity purpose, results for 
these 2 SNPs in the discovery sample are repeated. These 2 SNPs appeared in the second layer of CART analyses on LDL and fasting glucose levels. 
Results were obtained by fitting Generalized Additive Mixed Models for patients, controlling for age, sex, body mass index and smoking status. 
β: estimate; ref: reference; LDL:low-density lipoprotein; FG: fasting glucose. 
Patients taking lipid-lowering or antidiabetic medications were excluded from LDL and FG analyses, respectively. 
For FG analyses, patients in non fasting conditions were excluded from analyses.
S1 Table. Lipid-lowering drugs, antidiabetic drugs and antihypertensive drugs considered to 










Fenofibrate Gliclazide Amlodipin 
Fluvastatin Glimepiride Atenolol 
Pravastatin Insulin Bisoprolol 
Rosuvastatin Metformin Bosentan 





































S2 Table. Characteristics of psychiatric samples: discovery and replication samples 
Characteristics 
Discovery sample Replication sample p-
value7n median (range) n median (range) 
Male (%)  356 156 (43.8)  140 58 (41.4)  0.63 
Age, years 356 47  (12-96) 140 52  (15-97) 0.04 
Medication, n(%) 356   140   0.74 
    Amisulpride    28 (7.9) 13 (9.3)   
    Aripiprazole  32 (9)  10 (7.2)   
    Clozapine  25 (7.0)  11 (7.9)   
    Lithium 31 (8.6) 8 (5.7)   
    Mirtazapine 15 (4.2) 8 (5.7)   
    Olanzapine    41 (11.5)    12 (8.6)    
    Quetiapine  115 (32.4)   47 (33.8)    
    Risperidone    52(14.6)     26 (18.7)    
    Valproate  17 (4.8)   4 (2.9)    
Main diagnosis, n(%) 269   90   0.42 
   Organic mental disorders    10 (3.7)  8 (8.9)   
   Psychotic disorders   107 (39.8)  25 (27.8)    
   Schizoaffective disorders  21 (7.8)     10 (11.1)     
   Bipolar disorders    65 (24.2)   21 (23.3)   
   Depressive disorder    66 (24.5) 26 (28.9)   
Treatment duration, months 356 3 (1-12) 140 3 (1-12) 0.63 
Treatment duration1: 0 
Total cholesterol, mmol/l 
355
4.6 (2.1-8.4)   
   Hypercholesterolemia (≥ 5 mmol/l), 
n(%) 2 166 (46.8)     
High-density lipoprotein, mmol/l 
348
1.4 (0.6-3.3)   
    Hypocholesterolemia (≤ 1 mmol/l), 
n(%) 2 77 (22.1)     
Low-density lipoprotein, mmol/l 
338
2.6 (0.6-6.1)   
   Hypercholesterolemia (≥ 3 mmol/l), 
n(%) 2  148 (43.8)     
Triglycerides, mmol/l 3 
279
1.1 (0.4-8.5)   
    Hypertriglyceridemia (≥ 2 mmol/l), 
n(%) 2,3 51 (18.3)     
Glucose, mmol/l  
272
5.1 (3.5-10.3)   
    Hyperglycemia (≥ 5.6 mmol/l), n(%) 4 71 (26.1)   
Body mass index,  kg/m2 343
23.0 (13.3-
42.5)     
    Obesity (≥30 kg/m2), n(%) 45 (13.1)   
Waist circumference,  cm 
310
86 (54-136)   
    Obesity in women (≥80 cm) ,n(%) 5  112 (64)   
    Obesity in men (≥94 cm) ,n(%) 5 52 (38.5)   
 
 
Systolic blood pressure, mm Hg 
320
123 (70-214)   
    Hypertension (≥140 mm Hg) ,n(%) 6 102 (31.9)   
Diastolic blood pressure,  mm Hg 
320
75 (47-150)   
    Hypertension (≥90 mm Hg) ,n(%) 6 90 (28.1)   
Treatment duration1: 1 




5.1 (2.8-7.7) 0.21 
   Hypercholesterolemia (≥ 5 mmol/l), 
n(%) 2 109 (52.7) 54 (62.8) 0.11 




1.4 (0.7-2.8) 0.19 
    Hypocholesterolemia (≤ 1 mmol/l), 
n(%) 2 55 (26.7) 20 (23.0) 0.5 




3.0 (0.8-5.3) 0.25 
   Hypercholesterolemia (≥ 3 mmol/l), 
n(%) 2 96 (48.2) 47 (58) 0.13 




1.2 (0.4-4.6) 0.68 
    Hypertriglyceridemia (≥ 2 mmol/l), 
n(%) 2,3 41 (23.1) 18 (27.7) 0.46 




5.0 (4.1-20.8) 0.06 
    Hyperglycemia (≥ 5.6 mmol/l), n(%) 4 20 (17.4) 11 (25.0) 0.28 
Body mass index,  kg/m2 200
23.6 (13.4-
43.5) 77
24.3 (14.7-40.6) 0.57 
    Obesity (≥30 kg/m2), n(%) 27 (13.5) 14 (18.2) 0.32 




88 (58-126) 0.47 
    Obesity in women (≥80 cm) ,n(%) 5  65 (67) 29 (70.7) 0.67 
    Obesity in men (≥94 cm) ,n(%) 5 33 (36.7) 28 (46.4) 0.35 




122 (100-170) 0.47 
    Hypertension (≥140 mm Hg) ,n(%) 6 8 (21) 7 (35) 0.25 




75 (60-115) 0.92 
    Hypertension (≥90 mm Hg) ,n(%) 6 9 (23.7) 7 (35) 0.36 
Treatment duration1: 2 




5 (2.7-8.6) 0.29 
   Hypercholesterolemia (≥ 5 mmol/l), 
n(%) 2 134 (57.5) 58 (56.3) 0.84 




1.4 (0.6-2.7) 0.53 
    Hypocholesterolemia (≤ 1 mmol/l), 
n(%) 2 61 (26.3) 24 (23.3) 0.56 




3 (1.4-6.2) 0.19 
   Hypercholesterolemia (≥ 3 mmol/l), 
n(%) 2 114 (52) 55 (55.5) 0.56 




1.2 (0.4-4.1) 0.74 
    Hypertriglyceridemia (≥ 2 mmol/l), 
n(%) 2,3 45 (25.3) 19 (26) 0.9 
Glucose, mmol/l  147 4.9 (3.5-7.9) 69 5.1 (2.7-11.2) 0.32 
 
 
    Hyperglycemia (≥ 5.6 mmol/l), n(%) 4 29 (19.7) 13 (18.8) 0.88 
Body mass index,  kg/m2 229
23.7 (16.1-
44.1) 98
25.5 (14.3-50.2) 0.04 
    Obesity (≥30 kg/m2), n(%) 36 (15.7) 29 (29.6) 0.004 




95 (66-162) 0.03 
    Obesity in women (≥80 cm) ,n(%) 5  77 (78.6) 42 (77.8) 0.91 
    Obesity in men (≥94 cm) ,n(%) 5 51 (49.5) 26 63.4) 0.13 




120 (84-162) 0.77 
    Hypertension (≥140 mm Hg) ,n(%) 6 27 (18.6) 18 (23.7) 0.37 




77.5 (56-110) 0.36 
    Hypertension (≥90 mm Hg) ,n(%) 6 34 (23.6) 22 (28.9) 0.38 
Treatment duration1: 3 




5.2 (3.3-8.2) 0.25 
   Hypercholesterolemia (≥ 5 mmol/l), 
n(%) 2 103 (62) 50 (68.5) 0.34 




1.3 (0.7-4.8) 0.29 
    Hypocholesterolemia (≤ 1 mmol/l), 
n(%) 2 47 (29.2) 17 (23.9) 0.41 




3.1 (0.6-6.4) 0.75 
   Hypercholesterolemia (≥ 3 mmol/l), 
n(%) 2 85 (57.8) 39 (56.5) 0.86 




1.2 (0.5-3.7) 0.69 
    Hypertriglyceridemia (≥ 2 mmol/l), 
n(%) 2,3 32 (25.6) 16 (28.6) 0.67 




5.2 (3.1-13.6) 0.9 
    Hyperglycemia (≥ 5.6 mmol/l), n(%) 4 33 (27.1) 15 (27.8) 0.92 
Body mass index,  kg/m2 160
24.9 (15.2-
47.2) 62
25.5 (15.3-41.2) 0.77 
    Obesity (≥30 kg/m2), n(%) 34 (21.2) 15 (24.2) 0.63 




92 (48-137) 0.46 
    Obesity in women (≥80 cm) ,n(%) 5  58 (71.6) 21 (65.6) 0.53 
    Obesity in men (≥94 cm) ,n(%) 5 39 (56.5) 18 (62.1) 0.61 




120 (88-177) 0.76 
    Hypertension (≥140 mm Hg) ,n(%) 6 32 (23.7) 16 (25.4) 0.79 




77 (58-106) 0.5 
    Hypertension (≥90 mm Hg) ,n(%) 6 35 (25.9) 18 (28.6) 0.69 
 
¹ Treatment duration: period of the current psychotropic treatment. This variable was categorized into four categories according to 
the number of days of psychotropic treatment as follow: 0: 0 days i.e baseline before the prescription of the studied drug; 1: from 
≥10 to <45 days; 2: from ≥45 to <135 days; 3: from ≥135 to <535 days. 
2 Lipid levels thresholds were defined according to ESH/ESC guidelines(2). Patients with treated dyslipidemia (S2 Table) were also 
included in the abnormal lipid levels category. 
3 Triglyceride levels were collected in fasting conditions. 
4 Threshold for fasting glucose levels (≥5.6 mmol/l) was defined according to IDF definition(3). Patients with treated diabetes (S2 
Table) were also included in the abnormal glucose levels category. 
 
 
5 Waist circumference thresholds (≥80 cm for women and ≥94 cm for men) were defined according to IDF definition(3).  
6 Hypertension thresholds (≥140 mm Hg for systolic blood pressure and ≥ 90 mm Hg for diastolic blood pressure) were defined 
according to ESH/ESC guidelines(2). Patients with treated hypertension (S2 Table) were also included in the abnormal hypertension 
category. 
7 P values were calculated using Wilcoxon-Mann-Whitney tests or Chi2 tests between the two psychiatric samples. Values in bold 
are significant. 









S3 Table. Genotype frequencies in two Caucasian psychiatric samples. 





SH2B1 rs3888190 C>A   CC CA AA     0.36
Discovery sample 356 143 (40.3) 171 (47.9) 42 (11.7) 0.39 0.36   
   Replication sample  140 66 (47.14) 57 (40.71) 17 (12.14) 0.39 0.32   
RABEP1 rs1000940A>G   AA AG GG     0.35
Discovery sample 356 185 (51.9) 141 (39.6) 30 (8.4) 0.67 0.28   
   Replication sample  140 67 (48.2) 59 (42.4) 13 (9.3) 0.93 0.30   
 
Deviation from Hardy Weinberg Equilibrium (HWE) and minor allele frequencies (MAF) observed in our samples and 

























S1 Fig. Tree structure of the classification and regression tree (CART) analysis for the evolution of TC levels within the first 
category of psychotropic treatment duration (i.e from 10 to 45 days of treatment). Each node indicates the mean of TC 

























S2 Fig. a. Evolution of the proportion of patients with abnormal LDL values (≥3mmol/l or prescription of a lipid-lowering 
medication) during psychotropic treatment according to rs3888190C>A genotype. b. Overall proportion of patients with 
abnormal LDL values (≥3mmol/l or prescription of a lipid-lowering medication) according to rs3888190C>A genotype.  








S3 Fig. a. Evolution of the proportion of patients with abnormal fasting glucose values (≥5.6mmol/l or prescription of an 
antidiabetic medication) during psychotropic treatment according to rs1000940A>G genotype. The first two periods, as well 
as the last two periods of psychotropic treatment were pooled together for statistical power purposes. b. Overall proportion of 
patients with abnormal fasting glucose values (≥5.6mmol/l or prescription of an antidiabetic medication) according to 
rs1000940A>G genotype.  























S4 Fig. eQTL data of rs3888190 and its proxies (r2≥0.8) Cis-association data of significant SNPs influence on the expression of 
nearby genes were extracted from the Genotype-Tissue Expression (GTEx) project, a public source 
(http://www.gtexportal.org/home/) with available expression Quantative Trait Loci (eQTL) data of 7051 samples from 44 different 















S5 Fig. eQTL data of rs1000940 and its proxies r2≥0.8 Cis-association data of significant SNPs influence on the expression of 
nearby genes were extracted from the Genotype-Tissue Expression (GTEx) project, a public source 
(http://www.gtexportal.org/home/) with available expression Quantative Trait Loci (eQTL) data of 7051 samples from 44 different 
tissues and for genome-wide genetic variations (Illumina OMNI 5M SNP Array)(4) 
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